Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Sacubitril valsartan

Brand: Entresto®
NICE TA: 388
Indication: Treating symptomatic chronic heart failure with reduced ejection fraction (NICE TA388)
Disease category: Cardiovascular system
Commissioning responsibility: CCG
PbR excluded: No

Background

Sacubitril/valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:
• with New York Heart Association (NYHA) class II to IV symptoms and
• with a left ventricular ejection fraction of 35% or less and
• who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).

Recommendation

LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

For CSR & GP CCGs  only - Must be stabilised by secondary care before transfer to primary care. Initiated by consultant cardiologist

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Amber

Amber

Amber 0 with restrictions (see above)

Amber0

Amber0

Amber0